Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Aussie Government Panel Accuses TGA Of Laxity In Approvals

This article was originally published in PharmAsia News

Executive Summary

One arm of the Australian government is accusing the Therapeutics Goods Administration of slipshod review work that allows questionable drugs and medical devices on the market. The Prostheses and Devices Committee, a government-appointed panel, reported the TGA has cleared some products despite a lack of support by the clinical studies submitted for the approval process. The committee said some of its members, who include medical professionals, believe TGA's review procedures are inadequate. The committee is considering how to coordinate the federal process of approving products with the programs for funding them. (Click here for more

Latest Headlines
See All
UsernamePublicRestriction

Register

SC072671

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel